Abstract
Tyrosine kinase receptor dysregulation is closely associated with diseases such as non-small cell lung cancer (nsclc). Since small molecule inhibitors are able to target the tyrosine kinase receptor and limit its oncogenic activity, the development of targeted drugs has also been a focus of research. This article summarizes the relationship between tyrosine kinase receptors and non-small cell lung cancer, discusses the impact of specific molecular abnormalities in lung cancer on targeted therapies, and the progress of the inhibitor emergency. An integrated approach to treatment will help develop more effective treatment plans for patients that include molecular analysis, targeted therapy, and drug resistance. In addition, the article discusses the impact of personalized care on improving patient health.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
